Lipid-lowering therapy for the primary prevention of coronary heart disease

Journal of the American College of Cardiology

Volumn 33, Issue 7, 1999, Pages 2078-2082

  Gotto Jr, Antonio M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN;

ADULT; AGED; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID DIET; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW;

EID: 0344614497     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00114-X     Document Type: Article

References (33)

1. Manson J.E., Tosteson H., Ridker P.M., et al. The primary prevention of myocardial infarction (review). N Engl J Med. 326:1992;1406-1416.
2. Levine G.N., Keaney J.F. Jr, Vita J.A. Cholesterol reduction in cardiovascular disease clinical benefits and possible mechanisms (review) . N Engl J Med. 332:1995;512-521.
3. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
4. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 308:1994;367-373.
5. WHO Cooperative Trial Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-1118.
6. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1980;2:379-85.
7. WHO Cooperative Trial Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984;2:600-4.
8. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
9. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317:1987;1237-1245.
10. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
11. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
12. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 89:1994;1329-1445.
13. Jones PH, Grundy SM, Gotto AM Jr. Assessment and management of lipid abnormalities. In: Alexander RW, Schlant RC, Fuster V, eds. Hurst's The Heart, Arteries and Veins. New York: McGraw-Hill, 1998:1553-81.
14. Wysowski D.K., Gross T.P. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med. 150:1990;2169-2172.
15. Rossouw J.E., Lewis B., Rifkind B.M. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 323:1990;1112-1119.
16. Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., Furberg C.D. Cholesterol reduction yields clinical benefit a new look at old data . Circulation. 91:1995;2274-2282.
17. Jacobs D., Blackburn H., Higgins M., et al. Report of the Conference on Low Blood Cholesterol mortality associations . Circulation. 86:1992;1046-1060.
18. Lewis B., Paoletti R., Tikkanen M.J. Low Blood Cholesterol Health Implications . 1993;Current Medical Literature, London.
19. Muldoon M.F., Manuck S.B., Matthews K.A. Lowering cholesterol concentrations and mortality a quantitative review of primary prevention trials . BMJ. 301:1990;309-314.
20. Hulley S.B., Walsh J.M., Newman T.B. Health policy on blood cholesterol time to change directions . Circulation. 86:1992;1026-1029.
21. International Task Force. Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992;2:113-56.
22. Stamler J., Stamler R., Brown W.V., et al. Serum cholesterol doing the right thing . Circulation. 88:1993;1954-1960.
23. Gotto A.M. Jr. Lipid lowering, regression, and coronary events a review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting . Circulation. 92:1995;646-656.
24. West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997;79:756-62.
25. National Health Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-94, US NHANES III Examination Data File [CD-ROM]. DHHS public use data file 76200. Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
26. Johannesson M., Jönsson B., Kjekshus J., Olsson A.G., Pedersen T.R., Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 336:1997;332-336.
27. Pedersen T.R., Kjekshus J., Berg K., et al. Cholesterol lowering and the use of healthcare resources results of the Scandinavian Simvastatin Survival Study . Circulation. 93:1996;1796-1802.
28. Ashraf T., Hay J.W., Pitt B., et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 78:1996;409-414.
29. Goldman L., Weinstein M.C., Goldman P.A., Williams L.W. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 265:1991;1145-1151.
30. West of Scotland Coronary Prevention Study identification of high-risk groups and comparison with other cardiovascular intervention trials . Lancet. 348:1996;1339-1342.
31. Wilson P.W.F., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847.
32. Grundy S.M., Balady G.J., Criqui M.H., et al. Primary prevention of coronary heart disease guidance from Framingham. A statement for healthcare professionals from the AHA Task Force on Risk Reduction . Circulation. 97:1998;1876-1887.
33. Hoerger T.J., Bala M.V., Bray J.W., Wilcosky T.C., LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol. 82:1998;61-65.